IL146890A0 - Modified chimeric polypeptides with improved pharmacokinetic properties - Google Patents

Modified chimeric polypeptides with improved pharmacokinetic properties

Info

Publication number
IL146890A0
IL146890A0 IL14689000A IL14689000A IL146890A0 IL 146890 A0 IL146890 A0 IL 146890A0 IL 14689000 A IL14689000 A IL 14689000A IL 14689000 A IL14689000 A IL 14689000A IL 146890 A0 IL146890 A0 IL 146890A0
Authority
IL
Israel
Prior art keywords
chimeric polypeptides
pharmacokinetic properties
modified chimeric
improved pharmacokinetic
modified
Prior art date
Application number
IL14689000A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL146890(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL146890A0 publication Critical patent/IL146890A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
IL14689000A 1999-06-08 2000-05-23 Modified chimeric polypeptides with improved pharmacokinetic properties IL146890A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08
PCT/US2000/014142 WO2000075319A1 (en) 1999-06-08 2000-05-23 Modified chimeric polypeptides with improved pharmacokinetic properties

Publications (1)

Publication Number Publication Date
IL146890A0 true IL146890A0 (en) 2002-08-14

Family

ID=22480568

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14689000A IL146890A0 (en) 1999-06-08 2000-05-23 Modified chimeric polypeptides with improved pharmacokinetic properties
IL146890A IL146890A (en) 1999-06-08 2001-12-03 Chemical polypeptides are adapted with enhanced pharmacokinetic properties
IL190234A IL190234A0 (en) 1999-06-08 2008-03-17 Modified chimeric polypeptides with improved pharmacokinetic properties

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL146890A IL146890A (en) 1999-06-08 2001-12-03 Chemical polypeptides are adapted with enhanced pharmacokinetic properties
IL190234A IL190234A0 (en) 1999-06-08 2008-03-17 Modified chimeric polypeptides with improved pharmacokinetic properties

Country Status (33)

Country Link
EP (2) EP1183353B1 (no)
JP (2) JP4723140B2 (no)
KR (1) KR100659477B1 (no)
CN (3) CN101433715B (no)
AT (2) ATE417928T1 (no)
AU (2) AU779303B2 (no)
BE (1) BE2013C029I2 (no)
BR (2) BRPI0011407B8 (no)
CA (1) CA2376379C (no)
CY (2) CY1108883T1 (no)
CZ (2) CZ303656B6 (no)
DE (2) DE60041159D1 (no)
DK (2) DK1544299T3 (no)
ES (2) ES2237429T3 (no)
FR (1) FR13C0028I2 (no)
HK (3) HK1043388A1 (no)
HR (1) HRP20010908B1 (no)
HU (3) HU229156B1 (no)
IL (3) IL146890A0 (no)
LT (1) LTC1183353I2 (no)
LU (1) LU92195I2 (no)
ME (2) MEP3208A (no)
MX (1) MXPA01012630A (no)
NO (3) NO330775B1 (no)
NZ (1) NZ515913A (no)
PL (1) PL208247B1 (no)
PT (2) PT1544299E (no)
RS (1) RS50073B (no)
RU (1) RU2265661C2 (no)
SK (1) SK287332B6 (no)
UA (1) UA74146C2 (no)
WO (1) WO2000075319A1 (no)
ZA (1) ZA200110068B (no)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
CN1494552A (zh) 2001-01-19 2004-05-05 ·��ά��֢�о�Ժ Flt4(VEGFR-3)作为靶用于肿瘤成像和抗肿瘤治疗
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
WO2004108069A2 (en) 2002-05-04 2004-12-16 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
DK1608685T3 (da) * 2003-03-28 2007-06-11 Regeneron Pharma VEGF antagonister til behandlingen af diabetes
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP2354155B1 (en) * 2003-05-16 2017-05-03 Acorda Therapeutics, Inc. Fusion Proteins for Treatment of CNS
EP3211084B1 (en) 2003-05-16 2019-03-27 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
EP1626989A2 (en) * 2003-05-28 2006-02-22 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using vegf antagonists
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
WO2004110490A2 (en) * 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
WO2005016369A1 (en) * 2003-08-06 2005-02-24 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist in combination with radiation therapy
CA2566731C (en) 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
WO2005121176A1 (fr) * 2004-06-08 2005-12-22 Chengdu Kanghong Biotechnologies Co. Ltd Proteine chimerique inhibitrice d'angiogenese et utilisation associee
MXPA06014421A (es) 2004-06-10 2007-05-04 Regeneron Pharma Uso de inhibidores de vegf para el tratamiento de cancer humano.
JP2008503481A (ja) * 2004-06-18 2008-02-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 悪性胸膜滲出液の処置のためのｖｅｇｆインヒビターの投与および使用の方法
MX2007001241A (es) 2004-07-30 2007-07-11 Regeneron Pharma Metodos para tratar diabetes tipo i mediante el bloqueo de la actividad mediada de vegf.
WO2006031689A2 (en) * 2004-09-13 2006-03-23 Genzyme Corporation Multimeric constructs
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
EP1877438A2 (en) * 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
EP3195874A1 (en) 2005-03-25 2017-07-26 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
CA2623635C (en) 2005-09-26 2013-04-02 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
JP5489465B2 (ja) † 2005-12-16 2014-05-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
EP2364691B1 (en) 2006-06-16 2013-04-24 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
CA2664738C (en) 2006-09-29 2017-03-07 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7722864B2 (en) 2006-10-10 2010-05-25 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN101575379B (zh) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
NZ592591A (en) 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
WO2011047383A1 (en) 2009-10-16 2011-04-21 Oncomed Pharmaceuticals, Inc. Therapeutic combination and methods of treatment with a dll4 antagonist and an anti-hypertensive agent
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
PT2601214T (pt) 2010-08-06 2017-12-20 Genzyme Corp Composições de antagonistas de vegf e utilizações destes
WO2012093704A1 (ja) * 2011-01-07 2012-07-12 中外製薬株式会社 抗体の物性を改善させる方法
WO2012097019A1 (en) 2011-01-13 2012-07-19 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
CN104159926B (zh) 2011-12-01 2019-02-01 圆祥生命科技有限公司 补体和vegf途径的蛋白质抑制剂及其使用方法
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
WO2013169614A1 (en) 2012-05-07 2013-11-14 Allergan, Inc. Method of treating amd in patients refractory to anti-vegf therapy
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
PL3065761T3 (pl) 2013-11-05 2020-05-18 Allergan, Inc. Sposób leczenia schorzeń oczu za pomocą darpinu przeciwko vegf
US20170232199A1 (en) 2014-05-12 2017-08-17 Formycon Ag Pre-Filled Plastic Syringe Containing a VEGF Antagonist
TR201909951T4 (tr) 2014-07-18 2019-07-22 Sanofi Sa Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
US20170326106A1 (en) 2014-12-11 2017-11-16 Bayer Healthcare Llc Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
WO2017065559A1 (ko) 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
EP3377100A1 (en) 2015-11-18 2018-09-26 Formycon AG Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
EP3377040B8 (en) 2015-11-18 2024-06-05 SiO2 Medical Products, Inc. Pharmaceutical package for ophthalmic formulations
JP2019501687A (ja) 2015-11-18 2019-01-24 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆ拮抗薬を収容したプレフィルドプラスチックシリンジ
WO2017084616A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
AU2016364817B2 (en) 2015-12-03 2020-05-07 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
JPWO2018070390A1 (ja) 2016-10-12 2019-08-22 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
JP7116059B2 (ja) 2016-11-21 2022-08-09 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド アフリベルセプト製剤及びその使用
WO2018217995A1 (en) 2017-05-24 2018-11-29 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
EP3630062A2 (en) 2017-05-24 2020-04-08 SiO2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
JP7097433B2 (ja) 2017-08-17 2022-07-07 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 宿主細胞ガレクチンおよび他の夾雑物からグリコシル化タンパク質を精製する方法
CN111356471A (zh) 2017-11-20 2020-06-30 济世发展生物药业有限公司 包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途
PT3717636T (pt) * 2017-11-27 2023-05-30 4D Molecular Therapeutics Inc Cápsides variantes de vírus adeno-associado e utilização para inibir a angiogénese
PT3716992T (pt) 2017-11-30 2022-08-31 Regeneron Pharma Utilização de um antagonista do vegf para tratar distúrbios oculares angiogénicos
IL313285A (en) 2017-12-13 2024-08-01 Regeneron Pharma Apparatus and methods for support management of chromatography column substrate and related methods
CN111741761B (zh) * 2018-01-26 2023-04-18 加利福尼亚大学董事会 用于使用抗vegf剂治疗血管生成病症的方法和组合物
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
EP3790532A1 (en) 2018-05-10 2021-03-17 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (zh) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
EP3969564A1 (en) 2019-05-16 2022-03-23 Formycon AG Method for reducing methionine oxidation in recombinant proteins
US12059555B2 (en) 2019-09-03 2024-08-13 Amgen Inc. Injection device for drug delivery and packaging for the injection device
AU2020348947A1 (en) 2019-09-16 2022-03-10 Amgen Inc. Method for external sterilization of drug delivery device
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
JP2023502501A (ja) 2019-11-25 2023-01-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼内血管新生のための長時間作用型ｖｅｇｆ阻害剤
KR20220110555A (ko) 2019-12-06 2022-08-08 리제너론 파마슈티칼스 인코포레이티드 Vegf 미니-트랩 및 그의 사용 방법
MY193349A (en) 2019-12-06 2022-10-06 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
EP4110427A1 (en) 2020-02-24 2023-01-04 Amgen Inc. Containers and systems for use during external sterilization of drug delivery devices
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
WO2023092324A1 (zh) 2021-11-24 2023-06-01 苏州光度生物科技有限公司 多特异性配体结合分子及其应用
KR20240019034A (ko) * 2022-08-02 2024-02-14 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
DE60041159D1 (de) 2009-01-29
PT1544299E (pt) 2009-03-18
JP4723140B2 (ja) 2011-07-13
CZ303656B6 (cs) 2013-01-30
YU86901A (sh) 2004-05-12
NO330775B1 (no) 2011-07-11
EP1544299B1 (en) 2008-12-17
CZ302689B6 (cs) 2011-09-07
HK1132653A1 (en) 2010-03-05
SK287332B6 (sk) 2010-07-07
PL208247B1 (pl) 2011-04-29
DK1183353T3 (da) 2005-08-08
LU92195I2 (fr) 2013-07-15
BRPI0011407B1 (pt) 2018-09-25
PL352246A1 (en) 2003-08-11
CA2376379C (en) 2007-08-07
HUS1300052I1 (hu) 2016-08-29
BE2013C029I2 (no) 2019-03-06
ES2319305T3 (es) 2009-05-06
JP5273746B2 (ja) 2013-08-28
NO332559B1 (no) 2012-10-29
CY1108883T1 (el) 2014-07-02
ZA200110068B (en) 2002-12-06
CN100523187C (zh) 2009-08-05
CN101433715B (zh) 2013-04-17
CN103349781B (zh) 2015-04-01
JP2011024595A (ja) 2011-02-10
EP1544299A1 (en) 2005-06-22
NO20016036L (no) 2002-02-08
HK1185798A1 (en) 2014-02-28
NO2013010I1 (no) 2013-06-17
NZ515913A (en) 2004-01-30
AU779303B2 (en) 2005-01-13
CY2013019I2 (el) 2015-11-04
AU2005201365A1 (en) 2005-04-28
RU2265661C2 (ru) 2005-12-10
FR13C0028I2 (fr) 2014-05-16
HU230159B1 (hu) 2015-09-28
IL190234A0 (en) 2008-11-03
HK1043388A1 (en) 2002-09-13
NO20016036D0 (no) 2001-12-10
AU2005201365B2 (en) 2007-08-09
DE60019415D1 (de) 2005-05-19
LTC1183353I2 (lt) 2023-02-27
BR0011407A (pt) 2002-04-02
ATE293164T1 (de) 2005-04-15
CZ20014387A3 (cs) 2002-10-16
JP2003501089A (ja) 2003-01-14
AU5040400A (en) 2000-12-28
CA2376379A1 (en) 2000-12-14
FR13C0028I1 (fr) 2013-06-14
SK17522001A3 (sk) 2003-04-01
HUP0201515A2 (en) 2002-08-28
ME00024B (me) 2010-02-10
IL146890A (en) 2008-07-08
CN103349781A (zh) 2013-10-16
CY2013019I1 (el) 2015-11-04
BRPI0011407B8 (pt) 2021-05-25
WO2000075319A1 (en) 2000-12-14
LTPA2013009I1 (lt) 2013-06-25
EP1183353A1 (en) 2002-03-06
HU229156B1 (en) 2013-09-30
ES2237429T3 (es) 2005-08-01
HRP20010908A2 (en) 2005-04-30
EP1183353B1 (en) 2005-04-13
KR100659477B1 (ko) 2006-12-20
HRP20010908B1 (en) 2006-05-31
PT1183353E (pt) 2005-06-30
NO20100656L (no) 2002-02-08
NO2013010I2 (no) 2013-05-15
CN101433715A (zh) 2009-05-20
CN1369009A (zh) 2002-09-11
RS50073B (sr) 2009-01-22
KR20020019070A (ko) 2002-03-09
MXPA01012630A (es) 2002-07-22
ATE417928T1 (de) 2009-01-15
DE60019415T2 (de) 2006-03-09
MEP3208A (xx) 2010-02-10
UA74146C2 (uk) 2005-11-15
HUP0201515A3 (en) 2004-12-28
DK1544299T3 (da) 2009-03-23

Similar Documents

Publication Publication Date Title
HK1185798A1 (en) Modified chimeric polypeptides with improved pharmacokinetic properties
EP1173484A4 (en) TREATMENT OF FIBROSIS BY IL-13 ANTAGONISM AND IL-13 RECEPTOR CHAINS
EG24755A (en) Glucagon-like peptide -1 analogs.
EP2135617A3 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
PT1326630E (pt) Utilização de péptidos glp-2
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
HU0104018D0 (en) Use of antagonists of nr2b subtype of nmda receptor for medical treatment
AU2001259775A1 (en) Method for treating retinal degeneration with purinergic receptor agonists
AU5977501A (en) Method for treating retinal degeneration with purinergic receptor agonists
AU7918500A (en) Substituted diazepanes
ZA200309642B (en) Benzo (G) quinoline derivatives for treating glaucoma and myopia.
EP1371732A4 (en) FUSION PROTEIN WITH BETA 1,2-N-ACETYLGLUCOSAMINYL TRANSFERASE II ACTIVITY AND PRODUCTION METHOD THEREFOR
WO2003028651A3 (en) Antipsychotic agents stimulate neurogenesis in brain
Mulvihill Love's Labors Found——Deep in the Brain
ZA200203589B (en) Concomitant drugs for treating glaucoma.
AUPP924299A0 (en) A method for treating dyslexia amblyopia, exanopsia or strabismus
AU2002247731A1 (en) Pigmentary epithelium cell of the eye, the production thereof and the use of the same for treating diseases of the eye or of the central nervous system
AU2002333736A1 (en) Method for treating diabetic retinopathy

Legal Events

Date Code Title Description
KB Patent renewed